Maze Therapeutics, Inc. MAZE
Maze Therapeutics, Inc. (Nasdaq: MAZE) is a cardio-renal-metabolic drug developer. Its lead program, MZE829, is in Phase 2 for APOL1-mediated kidney disease. Its next catalyst on record is MZE829: Initiate pivotal trial, subject to regulatory feedback (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: MZE829 — Initiate pivotal trial, subject to regulatory feedback (H1 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| MZE829 | AMKD | small molecule | Phase 2 |
| MZE782 | PKU and CKD | small molecule | Phase 2 |
Recent results and decisions
- Aug 11, 2026started Phase 2 CIPheR proof-of-concept trial of MZE782 in PKU initiated and enrolling; topline data expected in 2027.
In line with previous guidance, Maze initiated the Phase 2 CIPheR proof-of-concept trial of MZE782 evaluating plasma phenylalanine (Phe) reduction in PKU and continues to enroll patients.
Filing - Mar 25, 2026positive Open-label Phase 2 HORIZON topline: MZE829 reduced uACR by a mean 35.6% at week 12 in broad AMKD (50% of patients with >30% reduction; 61.8% in FSGS, 48.6% in non-diabetic), no serious AEs.
The results demonstrated that treatment with MZE829 led to a clinically meaningful mean reduction in proteinuria, as measured by urinary albumin-to-creatinine ratio (uACR), of 35.6% at week 12 in broad AMKD patients, with 50% of patients achieving a greater than 30% reduction in uACR.
Filing - Mar 25, 2026started First patient dosed in global Phase 2 ESPRIT trial of MZE001 plus enzyme replacement therapy in late-onset Pompe disease (March 2026), triggering a $20 million Shionogi milestone.
In March 2026, Maze achieved a $20 million milestone under its collaboration agreement with Shionogi & Co., Ltd. in connection with the dosing of the first patient in ESPRIT, a global Phase 2 clinical trial evaluating MZE001 in addition to standard of care enzyme replacement therapy in patients with
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.